1887
  1. Home
  2. Eurosurveillance
  3. Volume 26, Issue 28, 15/Jul/2021
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

Evidence on COVID-19 vaccine efficacy/effectiveness (VE) in preventing asymptomatic SARS-CoV-2 infections is needed to guide public health recommendations for vaccinated people. We report interim results of a living systematic review. We identified a total of 30 studies that investigated VE against symptomatic and/or asymptomatic infection. In fully vaccinated individuals, VE against symptomatic and asymptomatic infections was 80–90% in nearly all studies. Fully vaccinated persons are less likely to become infected and contribute to transmission.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.28.2100563
2021-07-15
2024-12-21
/content/10.2807/1560-7917.ES.2021.26.28.2100563
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/28/eurosurv-26-28-3.html?itemId=/content/10.2807/1560-7917.ES.2021.26.28.2100563&mimeType=html&fmt=ahah

References

  1. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.  https://doi.org/10.1136/bmj.l4898  PMID: 31462531 
  2. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.  https://doi.org/10.1136/bmj.i4919  PMID: 27733354 
  3. Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021;397(10277):875-7.  https://doi.org/10.1016/S0140-6736(21)00448-7  PMID: 33610193 
  4. Andrejko K, Pry J, Myers JF, Jewell NP, Openshaw J, Watt J, et al. Early evidence of COVID-19 vaccine effectiveness within the general population of California. medRxiv. 2021.04.08.21255135.  https://doi.org/10.1101/2021.04.08.21255135 
  5. Britton A, Jacobs Slifka KM, Edens C, Nanduri SA, Bart SM, Shang N, et al. Effectiveness of the Pfizer-BioNTech COVID-19 vaccine among residents of two skilled nursing facilities experiencing COVID-19 outbreaks—Connecticut, December 2020–February 2021. MMWR Morb Mortal Wkly Rep. 2021;70(11):396-401.  https://doi.org/10.15585/mmwr.mm7011e3  PMID: 33735160 
  6. Chodick G, Tene L, Patalon T, Gazit S, Tov AB, Cohen D, et al. The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence. medRxiv. 2021:2021.01.27.21250612.  https://doi.org/10.2139/ssrn.3769977 
  7. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412-23.  https://doi.org/10.1056/NEJMoa2101765  PMID: 33626250 
  8. Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397(10282):1351-62.  https://doi.org/10.1016/S0140-6736(21)00628-0  PMID: 33798499 
  9. Glampson B, Brittain J, Kaura A, Mulla A, Mercuri L, Brett S, et al. North West London Covid-19 vaccination programme: real-world evidence for vaccine uptake and effectiveness. medRxiv. 2021.04.08.21254580.  https://doi.org/10.1101/2021.04.08.21254580 
  10. Guijarro C, Galán I, Martínez-Ponce D, Pérez-Fernández E, José Goyanes M, Castilla V, et al. Dramatic drop of new SARS-CoV-2 infections among health care workers after the first dose of the BNT162b2 mRNA Covid-19 vaccine. medRxiv. 2021.03.24.21254238.  https://doi.org/10.1101/2021.03.24.21254238 
  11. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Nationwide vaccination campaign with BNT162b2 in Israel demonstrates high vaccine effectiveness and marked declines in incidence of SARS-CoV-2 infections and COVID-19 cases, hospitalizations, and deaths. SSRN. 2021. Available from: https://ssrn.com/abstract=3811387
  12. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. Effectiveness of BNT162b2 mRNA vaccine against infection and COVID-19 vaccine coverage in healthcare workers in England, multicentre prospective cohort study (the SIREN Study). SSRN. 2021. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3790399
  13. Lumley SF, Rodger G, Constantinides B, Sanderson N, Chau KK, Street TL, et al. An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status. medRxiv. 2021.03.09.21253218.  https://doi.org/10.1101/2021.03.09.21253218 
  14. Monge S, Olmedo C, Alejos B, Lapeña MF, Sierra MJ, Limia A. Direct and indirect effectiveness of mRNA vaccination against SARS-CoV-2 infection in long-term care facilities in Spain. medRxiv. 2021.04.08.21255055.  https://doi.org/10.1101/2021.04.08.21255055 
  15. Moustsen-Helms IR, Emborg H-D, Nielsen J, Nielsen KF, Krause TG, Molbak K, et al. Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 vaccine in long-term care facility residents and healthcare workers–a Danish cohort study. MedRxiv. 2021.03.08.21252200.  https://doi.org/10.1101/2021.03.08.21252200 
  16. Pawlowski C, Lenehan P, Puranik A, Agarwal V, Venkatakrishnan A, Niesen MJ, et al. FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. MedRxiv. 2021.02.15.21251623.  https://doi.org/10.1101/2021.02.15.21251623 
  17. Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Lancet Infect Dis. 2021;S1473-3099(21)00289-9  PMID: 34174193 
  18. Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers - eight U.S. locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(13):495-500.  https://doi.org/10.15585/mmwr.mm7013e3  PMID: 33793460 
  19. Tande AJ, Pollock BD, Shah ND, Farrugia G, Virk A, Swift M, et al. Impact of the COVID-19 vaccine on asymptomatic infection among patients undergoing pre-procedural COVID-19 molecular screening. Clin Infect Dis. 2021;ciab229.  https://doi.org/10.1093/cid/ciab229  PMID: 33704435 
  20. Heymann AD, Zacay G, Shasha D, Bareket R, Kadim I, Sikron FH, et al. BNT162b2 vaccine effectiveness in preventing asymptomatic infection with SARS-CoV-2 virus: a nationwide historical cohort study. SSRN. 2021. Available from: https://ssrn.com/abstract=3796868
  21. Jones NK, Rivett L, Seaman S, Samworth RJ, Warne B, Workman C, et al. Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. eLife. 2021;10:10:e68808.  https://doi.org/10.7554/eLife.68808  PMID: 33830018 
  22. European Medicines Agency (EMA). Assessment report - COVID-19 Vaccine Janssen. Amsterdam: EMA. 2021. Available from: https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-janssen-epar-public-assessment-report_en.pdf
  23. Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021;385(2):187-9.  https://doi.org/10.1056/NEJMc2104974  PMID: 33951357 
  24. Bjork J, Inghammar M, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F. Effectiveness of the BNT162b2 vaccine in preventing COVID-19 in the working age population-first results from a cohort study in southern Sweden. medRxiv. 2021.04.20.21254636.  https://doi.org/10.1101/2021.04.20.21254636 
  25. Corchado-Garcia J, Hughes T, Cristea-Platon T, Lenehan P, Pawlowski C, Bade S, et al. Real-world effectiveness of Ad26. COV2. S adenoviral vector vaccine for COVID-19. SSRN. 2021. Available from: https://ssrn.com/abstract=3835737
  26. Fabiani M, Ramigni M, Gobbetto V, Mateo-Urdiales A, Pezzotti P, Piovesan C. Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021. Euro Surveill. 2021;26(17):2100420.  https://doi.org/10.2807/1560-7917.ES.2021.26.17.2100420  PMID: 33928898 
  27. Mason TF, Whitston M, Hodgson J, Watkinson RE, Lau Y-S, Abdulrazeg O, et al. Effects of BNT162b2 mRNA vaccine on Covid-19 infection and hospitalisation among older people: matched case control study for England. medRxiv. 2021. 04.19.21255461.  https://doi.org/10.1101/2021.04.19.21255461 
  28. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21(7):939-49.  https://doi.org/10.1016/S1473-3099(21)00224-3  PMID: 33930320 
  29. Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta K-D, et al. Impact of vaccination on SARS-CoV-2 cases in the community: a population-based study using the UK’s COVID-19 infection survey. medRxiv. 2021.04.22.21255913.  https://doi.org/10.1101/2021.04.22.21255913 
  30. Swift MD, Breeher LE, Tande AJ, Tommaso CP, Hainy CM, Chu H, et al. Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel. Clin Infect Dis. 2021;ciab361.  https://doi.org/10.1093/cid/ciab361  PMID: 33900384 
  31. Tang L, Hijano DR, Gaur AH, Geiger TL, Neufeld EJ, Hoffman JM, et al. Asymptomatic and symptomatic SARS-CoV-2 infections after BNT162b2 vaccination in a routinely screened workforce. JAMA. 2021;325(24):2500-2.  https://doi.org/10.1001/jama.2021.6564  PMID: 33956050 
  32. Angel Y, Spitzer A, Henig O, Saiag E, Sprecher E, Padova H, et al. Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. JAMA. 2021;325(24):2457-65.  https://doi.org/10.1001/jama.2021.7152  PMID: 33956048 
  33. Bero L, Lawrence R, Leslie L, Chiu K, McDonald S, Page M, et al. Comparison of preprints and final journal publications from COVID-19 studies: discrepancies in results reporting and spin in interpretation. medRxiv. 2021. 04.12.21255329.  https://doi.org/10.1101/2021.04.12.21255329 
  34. Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461-2462.  https://doi.org/10.1016/S0140-6736(21)01358-1  PMID: 34139198 
  35. Stowe J, Andrews N, Gower C, Gallagher E, Utsi L, Simmons R. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B. 1.617. 2) variant. Public Health England. 2021. Available from: https://media.tghn.org/articles/Effectiveness_of_COVID-19_vaccines_against_hospital_admission_with_the_Delta_B._G6gnnqJ.pdf
Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Thomas+Harder&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Harder Thomas</a>, <a href="/search?value1=Judith+Koch&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Koch Judith</a>, <a href="/search?value1=Sabine+Vygen-Bonnet&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Vygen-Bonnet Sabine</a>, <a href="/search?value1=Wiebe+K%C3%BClper-Schiek&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Külper-Schiek Wiebe</a>, <a href="/search?value1=Antonia+Pilic&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pilic Antonia</a>, <a href="/search?value1=Sarah+Reda&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Reda Sarah</a>, <a href="/search?value1=Stefan+Scholz&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Scholz Stefan</a>, <a href="/search?value1=Ole+Wichmann&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Wichmann Ole</a></span>. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. <a href="/content/ecdc">Euro Surveill.</a> 2021;26(28):pii=2100563. <a href="https://doi.org/10.2807/1560-7917.ES.2021.26.28.2100563" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2021.26.28.2100563</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 04 Jun 2021;&nbsp;&nbsp; <span class="generated">Accepted</span>: 14 Jul 2021 </span> </p>
/content/10.2807/1560-7917.ES.2021.26.28.2100563
/content/10.2807/1560-7917.ES.2021.26.28.2100563
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error